Tobam Sells 51,420 Shares of Bristol-Myers Squibb (NYSE:BMY)

Tobam lowered its holdings in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 44.2% during the first quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 64,862 shares of the biopharmaceutical company's stock after selling 51,420 shares during the period. Bristol-Myers Squibb comprises about 1.7% of Tobam's investment portfolio, making the stock its 17th biggest holding. Tobam's holdings in Bristol-Myers Squibb were worth $3,956,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors have also recently bought and sold shares of BMY. LaFleur & Godfrey LLC lifted its holdings in Bristol-Myers Squibb by 3.5% in the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after acquiring an additional 1,487 shares during the last quarter. Brighton Jones LLC raised its holdings in shares of Bristol-Myers Squibb by 33.4% during the fourth quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Sovran Advisors LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at approximately $274,000. Leavell Investment Management Inc. raised its holdings in shares of Bristol-Myers Squibb by 7.1% during the fourth quarter. Leavell Investment Management Inc. now owns 39,008 shares of the biopharmaceutical company's stock valued at $2,206,000 after buying an additional 2,582 shares during the last quarter. Finally, TFB Advisors LLC raised its holdings in shares of Bristol-Myers Squibb by 14.9% during the fourth quarter. TFB Advisors LLC now owns 4,787 shares of the biopharmaceutical company's stock valued at $271,000 after buying an additional 621 shares during the last quarter. Institutional investors own 76.41% of the company's stock.

Analyst Ratings Changes

A number of equities research analysts have recently weighed in on BMY shares. Cantor Fitzgerald reaffirmed a "neutral" rating and set a $55.00 price target on shares of Bristol-Myers Squibb in a report on Tuesday, April 22nd. The Goldman Sachs Group reaffirmed a "neutral" rating and set a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. Piper Sandler began coverage on Bristol-Myers Squibb in a report on Tuesday, April 22nd. They set an "overweight" rating and a $65.00 price target on the stock. William Blair reiterated a "market perform" rating on shares of Bristol-Myers Squibb in a research note on Friday, April 25th. Finally, Argus upgraded shares of Bristol-Myers Squibb to a "hold" rating in a research note on Friday, April 25th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Hold" and a consensus price target of $58.00.

Bristol-Myers Squibb Stock Down 1.9%

Shares of NYSE:BMY traded down $0.99 on Friday, reaching $49.71. The company had a trading volume of 9,394,854 shares, compared to its average volume of 12,995,538. The stock has a market capitalization of $101.15 billion, a P/E ratio of -11.25, a P/E/G ratio of 2.07 and a beta of 0.38. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a twelve month low of $39.35 and a twelve month high of $63.33. The stock has a 50-day moving average price of $48.71 and a 200 day moving average price of $54.73.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last released its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, topping analysts' consensus estimates of $1.50 by $0.30. The firm had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a negative net margin of 18.53% and a positive return on equity of 13.93%. The business's revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the business earned ($4.40) EPS. On average, equities analysts expect that Bristol-Myers Squibb will post 6.74 EPS for the current year.

Insiders Place Their Bets

In related news, EVP Samit Hirawat acquired 4,250 shares of the business's stock in a transaction dated Friday, April 25th. The stock was acquired at an average price of $47.58 per share, with a total value of $202,215.00. Following the completion of the transaction, the executive vice president now owns 83,513 shares of the company's stock, valued at approximately $3,973,548.54. This represents a 5.36% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Company insiders own 0.09% of the company's stock.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.